In the past decade, there have been a number of studies of the potential of pomegranate juice to support cardiovascular health and provide additional health benefits as well. Recently we reviewed a research report published in 2012 that looked at the cardiovascular and immune system benefits of pomegranate juice for hemodialysis patients. This was a randomized placebo controlled double-blind trial (a kind of research design that is likely to produce reliably objective findings). The patients were followed for one year as they used pomegranate juicee three times a week while continuing their dialysis treatments. The results:
Pomegranate juice intake resulted in a significantly lower incidence rate of the second hospitalization due to infections. Furthermore, 25% of the patients in the pomegranate juice group had improvement and only 5% progression in the atherosclerotic process, while more than 50% of patients in the placebo group showed progression and none showed any improvement.
And the conclusion:
Prolonged pomegranate juice intake improves nontraditional CV [cardiovascular] risk factors, attenuates the progression of the atherosclerotic process, strengthens the innate immunity, and thus reduces morbidity among HD [hemodialysis] patients.
Of course, this research involved a special group of patients, those on hemodialysis. But, as a well-designed study, it does, we think, provide a fairly strong endorsement of the health benefits of pomegranate juice.
For more on pomegranate juice, see the NYBC entry
Note that NYBC also carries the Douglas supplement Cardio-Edge, which includes pomegranate:
Reference: Shema-Didi, L et al. One year of pomegranate juice intake decreases oxidative stress, inflammation, and incidence of infections in hemodialysis patients: a randomized placebo-controlled trial. Free Radic Biol Med. 2012 Jul 15;53(2):297-304. doi: 10.1016/j.freeradbiomed.2012.05.013. Epub 2012 May 17.